These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
681 related articles for article (PubMed ID: 16426904)
21. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Tramper-Stranders GA; Wolfs TF; van Haren Noman S; van Aalderen WM; Nagelkerke AF; Nuijsink M; Kimpen JL; van der Ent CK Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233 [TBL] [Abstract][Full Text] [Related]
22. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis. De Rose V; Arduino C; Cappello N; Piana R; Salmin P; Bardessono M; Goia M; Padoan R; Bignamini E; Costantini D; Pizzamiglio G; Bennato V; Colombo C; Giunta A; Piazza A Eur J Hum Genet; 2005 Jan; 13(1):96-101. PubMed ID: 15367919 [TBL] [Abstract][Full Text] [Related]
23. A cystic fibrosis mutation associated with mild lung disease. Gan KH; Veeze HJ; van den Ouweland AM; Halley DJ; Scheffer H; van der Hout A; Overbeek SE; de Jongste JC; Bakker W; Heijerman HG N Engl J Med; 1995 Jul; 333(2):95-9. PubMed ID: 7539891 [TBL] [Abstract][Full Text] [Related]
24. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Dorfman R; Taylor C; Lin F; Sun L; Sandford A; Paré P; Berthiaume Y; Corey M; Durie P; Zielenski J; Pediatr Pulmonol; 2011 Apr; 46(4):385-92. PubMed ID: 20967843 [TBL] [Abstract][Full Text] [Related]
25. Update on antibiotics for infection control in cystic fibrosis. Kirkby S; Novak K; McCoy K Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706 [TBL] [Abstract][Full Text] [Related]
26. [Genotype and phenotype of gastrointestinal symptoms analysis in children with cystic fibrosis]. Iwańczak F; Smigiel R; Stawarski A; Pawłowicz J; Stembalska A; Mowszet K; Sasiadek M Pol Merkur Lekarski; 2005 Feb; 18(104):205-9. PubMed ID: 17877132 [TBL] [Abstract][Full Text] [Related]
27. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance]. Coman G; Petraru E; Dahorea C; Anton DT Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957 [TBL] [Abstract][Full Text] [Related]
29. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Rodman DM; Polis JM; Heltshe SL; Sontag MK; Chacon C; Rodman RV; Brayshaw SJ; Huitt GA; Iseman MD; Saavedra MT; Taussig LM; Wagener JS; Accurso FJ; Nick JA Am J Respir Crit Care Med; 2005 Mar; 171(6):621-6. PubMed ID: 15591474 [TBL] [Abstract][Full Text] [Related]
30. Paranasal sinus pathogens in children with cystic fibrosis: do they relate to lower respiratory tract pathogens and is eradication successful? Wilson P; Lambert C; Carr SB; Pao C J Cyst Fibros; 2014 Jul; 13(4):449-54. PubMed ID: 24713592 [TBL] [Abstract][Full Text] [Related]
31. Aquagenic wrinkling of the palms in cystic fibrosis: comparison with controls and genotype-phenotype correlations. Berk DR; Ciliberto HM; Sweet SC; Ferkol TW; Bayliss SJ Arch Dermatol; 2009 Nov; 145(11):1296-9. PubMed ID: 19917960 [TBL] [Abstract][Full Text] [Related]
32. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Emerson J; Rosenfeld M; McNamara S; Ramsey B; Gibson RL Pediatr Pulmonol; 2002 Aug; 34(2):91-100. PubMed ID: 12112774 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597 [TBL] [Abstract][Full Text] [Related]
34. Microbiologic and therapeutic aspects of Staphylococcus aureus in cystic fibrosis patients. Bauernfeind A; Hörl G; Przyklenk B Scand J Gastroenterol Suppl; 1988; 143():99-102. PubMed ID: 3164518 [TBL] [Abstract][Full Text] [Related]
35. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study. Pressler T; Frederiksen B; Skov M; Garred P; Koch C; Høiby N J Cyst Fibros; 2006 Jan; 5(1):9-15. PubMed ID: 16412706 [TBL] [Abstract][Full Text] [Related]
36. ENaCbeta and gamma genes as modifier genes in cystic fibrosis. Viel M; Leroy C; Hubert D; Fajac I; Bienvenu T J Cyst Fibros; 2008 Jan; 7(1):23-9. PubMed ID: 17560176 [TBL] [Abstract][Full Text] [Related]
37. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population. Bradbury R; Champion A; Reid DW Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887 [TBL] [Abstract][Full Text] [Related]
38. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059 [TBL] [Abstract][Full Text] [Related]
39. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Amin R; Lam M; Dupuis A; Ratjen F Pediatr Pulmonol; 2011 Jun; 46(6):554-8. PubMed ID: 21337727 [TBL] [Abstract][Full Text] [Related]
40. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels? Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]